Latest News - Biogen
Top Corporates Hub
Biogen
Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027
04.10.2026 10:08
Design Therapeutics initiated at Hold: DT-216P2 shows early FA RESTORE-FA gains; watch Q4 '26/Q1 '27 catalysts and cash runway. Click for more on DSGN stock.
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
02.10.2026 15:20
Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who started
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
02.10.2026 13:00
AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.
1 Profitable Stock Worth Investigating and 2 We Ignore
01.10.2026 11:41
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
1 Profitable Stock Worth Investigating and 2 We Ignore
01.10.2026 11:41
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
HLS Therapeutics Announces Board of Directors Changes
01.10.2026 11:00
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the "Board"), effective today. The appointments follow the departures of Dr. Kyle Dempsey and Christine Elliott. Following these changes, the Board comprises eight directors, six of whom are independent.
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
29.09.2026 04:23
Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.
Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?
23.09.2026 09:15
Biogen (BIIB) is back in focus after publishing adolescent subgroup data from its Phase 3 VALIANT trial of EMPAVELI in rare kidney diseases, a catalyst that gives investors fresh clinical context around the stock. For context, Biogen’s recent clinical and product news has landed against a backdrop of stronger trading action, with a 1-day share price return of 2.87% on the latest close at US$225.36 and a 90-day share price return of 12.91%. Investors are weighing kidney and Alzheimer’s updates...
Novo defends diversification push as CEO eyes deals beyond obesity
22.09.2026 04:53
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
Biogen: Growth Is Back, But It Came At A Price
17.09.2026 07:15
Biogen pivots to Leqembi/Skyclarys and the Apellis deal to revive growth, but upside looks limited.
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
16.09.2026 06:00
The First and Only Anti-Amyloid Treatment in Japan that Enable At-Home Administration for Alzheimer's Disease, a Progressive DiseaseTOKYO and CAMBRIDGE, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of the anti-amyloid beta (Aβ) protofibril antibody “LEQEMBI®” (brand name, generic name: lecanemab) has been approved in Japan as a new route of administration. LEQEMBI Pen is an autoinj
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
15.09.2026 04:02
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quart
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
15.09.2026 04:02
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley event. The company expects a series of late-stage clinical readouts to begin as soon as next quart
Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
14.09.2026 11:21
Biogen Inc. (BIIB) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 9:15 AM EDTCompany ParticipantsChristopher Viehbacher -...
Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit
08.09.2026 14:30
FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Technology Leadership Summit, qualified technology executives are encouraged to secure their seats now while limited seating remains available. The September 10 summit at The Harvard Club of Boston will bring together CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology leaders to discuss AI governance, Agen
Lilly Builds Neuroscience into a New Long-Term Growth Driver
08.09.2026 12:27
Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
04.09.2026 04:38
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
03.09.2026 11:06
Biogen (NasdaqGS: BIIB) and Eisai launched LEQEMBI IQLIK, a once-weekly subcutaneous injection for early Alzheimer's disease, now available in the U.S. for initiation and maintenance therapy. The treatment allows at-home dosing for eligible patients using a pre-filled syringe or autoinjector, following a step-up initiation schedule. LEQEMBI IQLIK is described as the first anti-amyloid therapy with an approved subcutaneous initiation option that can be started outside an infusion...
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
03.09.2026 04:00
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative DiseaseTOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (Chinese trademark: 乐意保®
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
03.09.2026 03:25
Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests. Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track...